GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Nymox Pharmaceutical Corp (OTCPK:NYMXF) » Definitions » 6-Month Price Index

Nymox Pharmaceutical (Nymox Pharmaceutical) 6-Month Price Index : 0.23 (As of May. 20, 2024)


View and export this data going back to 1997. Start your Free Trial

What is Nymox Pharmaceutical 6-Month Price Index?

6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago. It’s calculated by current share price divided by share price 6-months ago. As of today (2024-05-20), Nymox Pharmaceutical's 6-Month Price Index is 0.23.


Competitive Comparison of Nymox Pharmaceutical's 6-Month Price Index

For the Biotechnology subindustry, Nymox Pharmaceutical's 6-Month Price Index, along with its competitors' market caps and 6-Month Price Index data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Nymox Pharmaceutical  (OTCPK:NYMXF) 6-Month Price Index Calculation

6-Month Price Index is calculated as following:

6-Month Price Index=Current Share Price / Share Price 6-Months Ago

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Nymox Pharmaceutical  (OTCPK:NYMXF) 6-Month Price Index Explanation

Price Index (PI) also called momentum. Strategies involving Price Index are also known as momentum strategies as they allow investors to profit from a company’s stock price. 6-Month Price Index is an intermediate-term momentum that shows the price change relative to 6-month ago.

The investment strategy for momentum investors is to buy winners and sell losers. That is, buy stocks that performed well and sell stocks that performed poorly in the past.


Nymox Pharmaceutical 6-Month Price Index Related Terms

Thank you for viewing the detailed overview of Nymox Pharmaceutical's 6-Month Price Index provided by GuruFocus.com. Please click on the following links to see related term pages.


Nymox Pharmaceutical (Nymox Pharmaceutical) Business Description

Traded in Other Exchanges
N/A
Address
Bay & Deveaux Streets, Nassau, BHS
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and the treatment of low-grade localized prostate cancer. It markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. It operates in a single segment, which is research and development of products for the aging population. The company's geographical segments include Canada, United States, and Europe.
Executives
James George Robinson director 10 EAST LEE STREET, SUITE 2705, BALTIMORE MD 21202
Erik Danielsen officer: Chief Financial Officer 9900 CAVENDISH BLVD, ST LAURENT A8 H4M 2V2
Paul Averback director, 10 percent owner, officer: CEO C/O NYMOX PHARMACEUTICAL CORPORATION, 9900 CAVENDISH BLVD., SUITE 306, ST. LAURENT A8 H4M 2V2
Randall J Lanham director, officer: General Counsel

Nymox Pharmaceutical (Nymox Pharmaceutical) Headlines

From GuruFocus

May 2023 Market Cap Requirement Update

By Value_Insider Value_Insider 11-25-2022

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 07-02-2022

Nymox Shareholder Update

By GuruFocusNews GuruFocusNews 12-13-2021

Nymox Delisting from NASDAQ

By Marketwired 07-05-2023

Nymox Announces NYMOZARFEX Marketing Application is Accepted For Review

By GlobeNewswire GlobeNewswire 02-15-2023

NYMOX Receives Deficiency Letter from NASDAQ

By PurpleRose PurpleRose 07-14-2022

NYMOX Appeals Deficiency Letter

By GlobeNewswire GlobeNewswire 01-06-2023

NYMOX Receives RTF letter from FDA

By GuruFocusNews GuruFocusNews 06-22-2022

NYMOX Provides Current Update

By Marketwired Marketwired 10-11-2021

NYMOX Updates Shareholders

By PurpleRose PurpleRose 07-15-2022